India Pharma Outlook Team | Monday, 16 November 2026
The Mankind Pharma ensartinib deal marks a new development in India's oncology market, with Mankind Pharma entering an exclusive licensing agreement with China's Betta Pharmaceuticals.
The agreement grants Mankind Pharma rights to develop, manufacture, register and commercialize ensartinib in India.
The targeted cancer therapy is indicated for adults with ALK-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK inhibitor.
The partnership strengthens Mankind Pharma's specialized medicines portfolio while introducing another targeted treatment opportunity into India's evolving lung cancer treatment landscape, subject to regulatory approvals.
Also Read: 5 Women Leaders Driving India's Pharma and Healthcare Innovation
Under the agreement, Mankind Pharma will make an upfront payment, alongside potential development and sales milestone payments and royalties based on annual net sales in India.
The company will receive exclusive rights to develop, manufacture, register and commercialize ensartinib in India.
The partnership supports its strategy of expanding its oncology portfolio through collaborations with international pharmaceutical companies.
Ensartinib is an ALK inhibitor that blocks signaling pathways involved in cancer cell growth.
The US FDA approved the drug in December 2024 for eligible adults with ALK-positive advanced or metastatic NSCLC who have not previously received an ALK inhibitor.
In the Phase III eXALT3 trial involving 290 patients, ensartinib demonstrated median progression-free survival of 25.8 months, compared with 12.7 months for crizotinib. The FDA reported no statistically significant overall survival difference between the treatments.
The agreement creates an opportunity for Mankind Pharma to enter a specialized segment of India's oncology market.
However, access to targeted therapies depends on molecular diagnostics that identify genetic alterations such as ALK rearrangements.
Techniques including next-generation sequencing and fluorescence in situ hybridization help identify eligible patients. Pricing, regulatory approval and competition from existing ALK inhibitors will influence the drug's commercial prospects.
The Mankind Pharma ensartinib deal therefore represents both a portfolio expansion opportunity and a potential addition to India's targeted lung cancer treatment options.